| Identification | Back Directory | [Name]
SCR7 | [CAS]
1533426-72-0 | [Synonyms]
SCR7
CS-1733
SCR7 USP/EP/BP
5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol
5,6-bis((E)-benzylideneamino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one
2,3-Dihydro-5,6-bis[(E)-(phenylmethylene)amino]-2-thioxo-4(1H)-pyrimidinone
4(1H)-Pyrimidinone, 2,3-dihydro-5,6-bis[(E)-(phenylmethylene)amino]-2-thioxo- | [Molecular Formula]
C18H14N4OS | [MDL Number]
MFCD28900670 | [MOL File]
1533426-72-0.mol | [Molecular Weight]
334.4 |
| Chemical Properties | Back Directory | [Melting point ]
206-208°C | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
7.93±0.25(Predicted) | [color ]
Light Yellow |
| Hazard Information | Back Directory | [Uses]
SCR7 is an anti cancer molecule that selectively inhibits one of the DNA double strand break (DSB) repair pathways, non-homologous end joining (NHEJ). | [in vivo]
SCR7 (SCR7 pyrazine; 10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan[1]. | Animal Model: | BALB/c mice injected with breast adenocarcinoma cells[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) | | Result: | Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan.
|
| [IC 50]
DNA Ligase IV; CRISPR/Cas9 | [storage]
Store at -20°C |
|
|